Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

Roche Basel Switzerland

Roche planning ocrelizumab filings in early 2016

Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

- PMLiVE

Tantalising data for Baxter spin-off’s haemophilia therapy

Early-stage testing shows promise as a potentially transformative treatment

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

Sobi launches disease awareness app with UK hospital

Pharma firm links with GOSH on helping children with haemophilia

Roche Basel Switzerland

Roche moves closer to US filing for alectinib

Results showed alectinib able to shrink tumours in half of cases

Shire Basingstoke

Shire enters research partnership for rare eye disease

Will work with Foundation Fighting Blindness on treatment for adRP

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links